Research Article
Hydroxytyrosol Ameliorates Intervertebral Disc Degeneration and Neuropathic Pain by Reducing Oxidative Stress and Inflammation

Haichao Yu,1,2 Zhen Zhang,2,3 Fahong Wei,4 Guowei Hou,5 Yonggang You,6 Xiangyu Wang,7 Shiqi Cao,2 Xiaoqing Yang,2 Weibo Liu,2 Shaofu Zhang,2 Fanqi Hu,2 and Xuesong Zhang1,2

1School of Medicine, Nankai University, Tianjin, China
2Department of Orthopedics, The Fourth Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, China
3Medical School of Chinese People’s Liberation Army General Hospital, Beijing, China
4Department of Clinical Laboratory, Linyi Central Hospital, Linyi, Shandong, China
5Department of Orthopedics, PKU Care Luzhong Hospital, Zibo, Shandong, China
6Department of Orthopedics, 926th Hospital of Joint Logistic Support Force, The Affiliated Hospital of Kunming University of Science and Technology, Yunnan, China
7Department of Pain Medicine, The First Medical Center, Chinese People’s Liberation Army General Hospital, Beijing, China

Correspondence should be addressed to Fanqi Hu; hufanqi301@163.com and Xuesong Zhang; zhangxuesong301@163.com

Received 21 June 2022; Revised 27 August 2022; Accepted 22 September 2022; Published 2 November 2022

Academic Editor: Mayur Parmar

Copyright © 2022 Haichao Yu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Low back pain (LBP) seriously affects human quality of life. Intervertebral disc degeneration (IVDD) is the main pathological factor that leads to LBP, but the pathological mechanism underlying IVDD has not been fully elucidated. Neuropathic pain caused by IVDD is an important pathological factor affecting people’s daily lives. Therefore, it is very important to identify therapeutic drugs to ameliorate IVDD and secondary neuropathic pain. Hydroxytyrosol (HT) is a natural compound derived from olive leaves and oil and has anti-inflammatory, antioxidant, and antitumor activities and other properties. In this study, TNF-α-stimulated human nucleus pulposus cells (HNPCs) were used to simulate the local inflammatory microenvironment observed in IVDD in vitro to explore the role of HT in alleviating various pathological processes associated with IVDD. A rat needle puncture model was used to further explore the role of HT in alleviating IVDD. Lipopolysaccharide (LPS) was used to stimulate microglia in vitro to comprehensively explore the role of HT in alleviating neuropathic pain, and a rat model involving chronic compression of the dorsal root ganglion (CCD) was established to simulate the neuropathic pain caused by IVDD. This study suggests that HT reduces the expression of cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome, a disintegrin and metalloproteinase with thrombospondin motifs-4 (ADAMTS-4) and matrix metalloproteinase-13 (MMP-13); inhibits the production of mitochondrial reactive oxygen species (ROS); and maintains mitochondrial homeostasis. Thus, HT appears to reduce the rate of apoptosis and mitigate the loss of major intervertebral disc components by inhibiting the nuclear factor kappa-B (NF-κB) signaling pathway. Moreover, HT inhibited the secretion of COX-2, tumor necrosis factor-α (TNF-α), interleukin (IL)-6, IL-1β, and iNOS and activation of the NLRP3 inflammasome in microglia by inhibiting the phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) and extracellular regulated protein kinase (ERK) signaling pathways. In conclusion, HT plays a protective role against IVDD and secondary neuropathic pain by inhibiting the NF-κB, PI3K/AKT, and ERK signaling pathways.

Hindawi
Oxidative Medicine and Cellular Longevity
Volume 2022, Article ID 2240894, 21 pages
https://doi.org/10.1155/2022/2240894
1. Introduction

Low back pain (LBP) is a common symptom in orthopedic patients. Research suggests that up to 84% of the global population will experience LBP in their lifetime [1, 2]. Intervertebral disc degeneration (IVDD) is the main pathological factor that causes LBP [3, 4]. The treatment of IVDD remains a controversial topic; treatment options include rest, pain medication, physical therapy, and surgery [5]. These methods are designed to relieve the patient’s pain but not to repair the damaged intervertebral disc (IVD). IVDD is an extremely complex pathological process. Abnormal mechanical stress, sudden trauma, bacterial infection, smoking, aging, and other pathogenic factors lead to the increased expression of inflammatory cytokines (such as interleukin (IL)-1β, IL-6, IL-17, and tumor necrosis factor-α (TNF-α)) in nucleus pulposus (NP) cells. The release of inflammatory cytokines leads to an increase in the expression of major catabolic enzymes (a disintegrin and metalloproteinase with thrombospondin motifs-4, 5 (ADAMTS-4, 5) and matrix metalloproteinase-13 (MMP-13)) in NP cells, resulting in the degradation of the extracellular matrix (ECM) and an imbalance between catabolic and anabolic metabolism in NP cells and the occurrence of IVDD [6].

Treatment of NP cells with TNF-α, a traditional inflammatory cytokine, has been widely used to establish IVDD models in vitro [7]. TNF-α triggers many pathological processes involved in IVDD through the activation of the NF-κB signaling pathway, including the secretion of a variety of proinflammatory cytokines (IL-1β, IL-6, and IL-8), the production of MMPs and ADAMTSs that promote ECM degradation, increased decomposition of collagen-2 (coll-2), and aggrecan, and damage to the structure of IVDs. TNF-α exacerbates IVD by activating the NOD-like receptor thermal protein domain associated protein 3 (NLRP3) inflammasome, thus mediating mitochondrial dysfunction and reactive oxygen species (ROS) production in NP cells [7].

Mitochondria are the main organelles producing ROS [8]. Mitochondria are the target of ROS, and the accumulation of ROS alters cellular metabolism, causing oxidative damage to IVD cells and leading to the activation of the NLRP3 inflammasome and the release of inflammatory cytokines [9]. The overproduction of ROS substantially inhibits matrix synthesis and upregulates the expression of proteases that cause matrix degradation in IVD cells [10]. ROS can cause oxidative damage to mtDNA and respiratory enzymes, resulting in the imbalance and dysfunction of mitochondrial energy metabolism and thus leading to apoptosis and the exacerbation of IVDD. Therefore, reducing the inflammatory response in the local microenvironment of IVDs, improving mitochondrial function and inhibiting the activation of the NLRP3 inflammasome are important strategies to delay IVDD progression.

The occurrence of neuropathic pain seriously affects patient quality of life and makes treatment difficult [11]. Neuropathic pain is caused by damage to the peripheral or central nervous system and is characterized by spontaneous pain and hyperalgesia in response to innocuous and noxious stimulation [12–14]. The exacerbation of IVDD leads to annulus fibrosus (AF) tears and NP herniation. When disc degeneration results in disc herniation, compression of adjacent nervous system structures, such as nerve roots or dorsal root ganglia, occurs; this compression causes peripheral nerve damage and aggravates neuropathic pain, since the damaged sensory neurons produce inflammatory cytokines and chemokines that activate microglia and astrocytes [15, 16].

Inflammatory cytokines are important initiators and aggravators of neuropathic pain. Accumulating evidence suggests that proinflammatory cytokines (IL-1β, IL-6, cyclooxygenase-2 (COX-2), inducible nitric oxide synthase (iNOS), and TNF-α) are strongly involved in the pathogenesis of neuropathic pain [17–19]. In addition, the NLRP3 inflammasome has been widely reported to promote neuroinflammatory responses, leading to the worsening of neuropathic pain [20–22]. Proinflammatory cytokines are upregulated in injured peripheral nerves and causes chronic neuroinflammation while activating microglia and astrocytes in the spinal dorsal horn (SDH), which play key roles in neuropathic pain [23]. Microglia are necessary for the maintenance, support, protection, and monitoring of the central nervous system [24]. Substantial microglial hyperplasia in the SDH leads to local inflammatory responses that aggravate neuropathic pain [18, 25]. Microglia interact with neurons related to pain transmission and increase the excitability of these neurons, leading to the occurrence and progression of neuropathic pain [26]. Therefore, inhibiting the inflammatory response is an important way to alleviate neuropathic pain. Chronic compression of the dorsal root ganglion (CDG) is one of the important methods used to study neuropathic pain, and it has become an important disease model to simulate the neuropathic pain caused by disc herniation and spinal canal stenosis due to its direct compression of the dorsal root ganglion [16]. Therefore, we established a rat model of CDG to simulate local nerve compression caused by disc herniation and to study the mechanism by which hydroxytyrosol (HT) alleviates neuropathic pain.

HT is a natural phenol and the most biologically active component in olive leaves and olive oil. HT has multiple biological effects, and its anti-inflammatory and antioxidant effects have been widely studied. HT exerts its strong anti-inflammatory effects by inhibiting the expression of lipopolysaccharide (LPS)-mediated inflammatory cytokines (TNF-α and IL-1β) [27] and by inhibiting the expression of MMP-9 and COX-2 in activated human monocytes [28]. Among the various phenols in olives, HT has the strongest antioxidant activity due to its abilities to supply electrons in the ortho position of its hydroxyl group and to form stable hydrogen bonds with the phenoxyl radical [27, 29]. Various studies have demonstrated that HT has therapeutic effects in cancer, neurodegenerative diseases, rheumatoid arthritis, osteoarthritis, and osteoporosis [30–33]. Previous studies have shown that HT-20 can inhibit acute inflammation and hyperalgesia induced by carrageenan in rats and reduce the local expression levels of IL-1β and TNF-α in rat tissues [34]. In a double-blind clinical trial, HT led to significantly better Japanese Orthopaedic Association (JOA) scores and visual analog scale scores than placebo.
in patients, demonstrating that HT is effective in reducing pain in gonarthrosis [35]. Moreover, HT inhibits several important pathological processes related to the occurrence and development of osteoarthritis; for example, HT reduces the production of important inflammatory cytokines, improves the local metabolic microenvironment, and inhibits the oxidative stress response [32, 36]. However, the mechanisms by which HT alleviates IVDD and neuropathic pain have not been reported. In the present study, we investigated the mechanisms by which HT alleviates neuropathic pain and IVDD.

2. Materials and Methods

2.1. Ethics Statement and Human Nucleus Pulposus Cell (HNPC) Extraction. The IVD tissues of 7 patients with IVDD were collected at Chinese PLA General Hospital (Beijing, China). The extraction of primary HNPCs was carried out according to a previously published study [37]. Briefly, NP tissues were cut into 1 mm³ pieces and digested with trypsin and type II collagenase. After 4 h of digestion, we used a 70 μm sterile cell filter to filter the digested HNPCs. The HNPCs were washed three times to remove the remaining type II collagenase and then seeded in petri dishes [37].

2.2. HNPC and Microglia Culture. HNPCs were divided into four groups and cultured under different conditions: PBS, LPS (50 ng/mL) (ABclonal, China), TNF-α + HT (20 μM) (MedChemExpress, China), and TNF-α + HT (100 μM). Rat microglia (Procell Life Science & Technology Co., Ltd.) were divided into four groups and cultured under different conditions according to a previous study [38]: PBS, LPS (1 μg/mL) (PeproTech, USA), LPS + HT (20 μM), and LPS + HT (100 μM).

2.3. Cell Viability. Cell viability was determined using the CCK-8 assay (Dojindo, Japan) following the manufacturer’s instructions. The HNPC suspension (10⁵ cells) was added to 96-well plates. The culture plates were placed in an incubator for preculture. Ten microliters of CCK-8 solution was added to each well, and the cells were incubated for 2 h or 48 h with 50 ng/mL TNF-α and 20 or 100 μM HT or were left untreated. Microglia were incubated for 24 h with 1 μg/mL LPS and 20 or 100 μM HT or were left untreated. Total RNA was extracted from HNPCs and microglia in each group with an RNA extraction kit (Yishan Biotechnology, China) and reverse transcribed into cDNA with a 20 μL reverse transcription kit (Yishan Biotechnology, 2 × RealStar Power SYBR Real-time Quantitative PCR Mix (High ROX) (Genstar, China) on a 7500 RT-PCR system (ABI, USA) was used to conduct qRT-PCR. Table 1 lists all the nucleotide sequences of the primers used in this experiment.

2.4. Rats. Two-month-old Sprague-Dawley rats were obtained from Beijing Vitalstar Biotechnology Co., Ltd. All rats were randomly assigned to 3 groups (N = 5 per group). After successfully anesthetizing the rats, we used X-ray to assess the Co6/7 intervertebral space of the rats. A 20 G puncture needle was used to penetrate the AF of the IVD to the center of the NP, rotated 360°, and then removed after one minute. Two microliters of HT (100 μM) was injected slowly for approximately 8 seconds using a Hamilton microsyringe with a 33 G needle on day 2 after the IVDD model was established.

All rats were randomly assigned to 4 groups (N = 5 per group). Two-month-old SD rats were anesthetized, the right paravertebral muscle of the L4-5 segment of rats was separated to expose the right lamina and the outer edge of the lamina, and L-shaped titanium rods (approximately 4 mm at one end and 3 mm at the other end) with a diameter of 0.63 mm were inserted into the L4 and L5 foramen. The rods were inserted into the foramen at 30° to the dorsal midline and 10° to the vertebral horizontal line [16]. In the sham group, only the L4 and L5 laminae and the outer edge of the lamina were exposed. The rats in the CCD model group (N = 5) were treated with intrathecal injection on the second day after the operation, and 10 μL HT (100 μm) was injected slowly for approximately 40 seconds.

2.5. Assessment of Pain Behaviors. Three researchers assessed the rats’ behavioral scores separately and in a double-blind manner. As previously reported [39], beginning on Day 0 postoperatively, the paw withdrawal mechanical threshold (PWMT) was assessed by the same researcher every two days using the BME-404 electronic mechanical pain detector (Chinese Academy of Medical Sciences, CAMS, Beijing, China), and thermal paw withdrawal latency (TPWL) was assessed by the same researcher every two days using the BME-410C thermal analgesia tester (CAMS).

2.6. Quantitative Real-Time PCR (qRT-PCR). HNPCs were incubated for 24 h with 50 ng/mL TNF-α and 20 or 100 μM HT or were left untreated. Microglia were incubated for 24 h with 1 μg/mL LPS and 20 or 100 μM HT or were left untreated. Total RNA was extracted from HNPCs and microglia in each group with an RNA extraction kit (Yishan Biotechnology, China) and reverse transcribed into cDNA with a 20 μL reverse transcription kit (Yishan Biotechnology, 2 × RealStar Power SYBR Real-time Quantitative PCR Mix (High ROX) (Genstar, China) on a 7500 RT-PCR system (ABI, USA) was used to conduct qRT-PCR. Table 1 lists all the nucleotide sequences of the primers used in this experiment.

2.7. Western Blotting (WB) Analysis. HNPCs were incubated for 1 h or 48 h with 50 ng/mL TNF-α and 20 or 100 μM HT or were left untreated. Microglia were incubated for 1 h or 48 h with 1 μg/mL LPS and 20 or 100 μM HT or were left untreated. The SDH was collected from the rats and lysed for 1 h with 100-150 μL protein extraction buffer (1% PMSF+RIPA); the total protein contents in microglia and HNPCs were then extracted. The proteins were separated and transferred to polyvinylidene fluoride (PVDF) membranes. The bands were incubated with primary antibodies (all at 1:1000 dilution), including antibodies targeting NLRP3, COX-2, MMP-13, iNOS, ADAMTS-4, Bcl-2, cleaved caspase-3 (c-caspase3), Bax, IL-6, TNF-α, phosphorylated p65, p65, phosphorylated-AKT, p-AKT, AKT, phosphorylated-ERK, ERK, and GAPDH (1:5000, Proteintech, China) (Table 2), and secondary antibodies (1:5000, Proteintech, China). The protein bands were detected using a Tanon 5200 imaging system (Tanon, China).

2.8. Flow Cytometry. A flow cytometry assay was performed after the cells had been stained with propidium iodide (PI) and annexin V-FITC at 25°C for 20 min using the BD Biosciences Assay Kit (USA). A BD FACSCalibur Flow Cytometer (BD Biosciences, USA) was used for analysis.
2.9. JC-1 Assay. A Beyotime Biotechnology (China) assay kit was used for the JC-1 experiment. In brief, HNPCs were incubated with JC-1 staining solution at 37°C for 30 min and then washed three times using 1X JC-1 buffer.

2.10. Mitochondrial Permeability Transition Pore (Mptp) Assay. An Mptp Assay Kit (Beyotime Biotechnology) was used to investigate the opening of the Mptp. In brief, HNPCs were incubated with calcine AM staining solution at 37°C for 45 min and then with preheated culture solution at 37°C for 30 min, washed with PBS 2-3 times, and then added to detection buffer solution for observation under a fluorescence microscope.

2.11. ROS Assay. Dichlorodihydrofluorescein diacetate (DCFH-DA) was added to fresh serum-free medium at a dilution ratio of 1:1000 and added dropwise to the cell culture plate for cell incubation at 37°C for 20-30 min according to the instructions of the ROS assay kit (Beyotime Biotechnology) [37].

2.12. Histological Staining. Hematoxylin and eosin (HE) staining (G1120, Solarbio, China), Safranin O-fast green (SO-FG) staining (Servicebio, China), and Sirius red staining (G1018, Servicebio, China) were carried out following the manufacturer’s procedures. A Pannoramic MIDI scanner (3DHISTECH, Hungary) was used to capture images.

**Table 1:** The nucleotide sequences of the primers used in this experiment.

| Source | Target | Forward primer, 5′-3′ | Reverse primer, 5′-3′ |
|--------|--------|-----------------------|----------------------|
| Human  | COX-2  | GGAACTTTCTGGTCCCTTCA  | TGGTTTTGGAGTGTTTTCA  |
|        | iNOS   | GCCAAGCTGAAATTTGAATGAGGA | TTCTGTCCGCGACCTTTAAC |
|        | MMP-13 | TGCTGATTCTCCTTCAAGGA  | ATGCATCCAGGCCGTCTGGC |
|        | ADAMTS-4 | ACCCAAGCATCCGCAATC    | CAGGTCCTGACGTTAAACA  |
|        | NF-κB1 | ATTGGAACACTTTGAAGCAAGC | CGGAAAGAAGATGGAAGAAC |
|        | GAPDH  | GCACCGTCAAGGCTGAGAAC | TGGTGAAGAGCGCAGTGGAA |
| Rat    | COX-2  | CTACACCAGGGCCCTTCC    | TCCAGAATTCTTTTGAATCAG |
|        | iNOS   | CACCACCCCTCCTTCAAC    | CAATCCACAACTCAGCCTAA |
|        | IL-6   | AAGCCAGAGTCATTGCAAGC  | GGTCCTGACCATACTCCTTC |
|        | IL-1β  | AAATTGCTCTGCTGTCTGA   | CAAAGGCAAGGATTTTGTCT |
|        | GAPDH  | CCACCACTGCTTCGCCCCCC  | GCAGTGATGGCAGTGACTTGG |

**Table 2:** Antibodies used in this experiment.

| Primary antibody | Catalog number | Manufacturer |
|------------------|----------------|--------------|
| Anti-NLRP3       | A5652          | ABclonal     |
| Anti-COX-2       | A1253          | ABclonal     |
| Anti-MMP13       | A11148         | ABclonal     |
| Anti-iNOS        | A14031         | ABclonal     |
| Anti-ADAMTS-4    | BS-4191R       | Bios         |
| Anti-Bcl-2       | A1105          | ABclonal     |
| Anti-cleaved caspase-3 | 9664 | Cell signaling technology |
| Anti-Bax         | A19684         | ABclonal     |
| Anti-IL-6        | A2447          | ABclonal     |
| Anti-TNF-α       | 60291-1-Ig     | Proteintech  |
| Anti-phosphorylated p65 (anti-p-p65) | AF2006 | Affinity |
| Anti-p65         | 3033           | Cell signaling technology |
| Anti-phosphorylated AKT (anti-p-AKT) | 9271 | Cell signaling technology |
| Anti-AKT         | 9272           | Cell signaling technology |
| Anti-phosphorylated ERK (anti-p-ERK) | 9101 | Cell signaling technology |
| Anti-ERK         | 9102           | Cell signaling technology |
| Anti-GAPDH       | 10494-1-AP     | Proteintech  |
| Anti-col-2       | AF0135         | Affinity     |
| Anti-aggrecan    | DF7561         | Affinity     |
| Anti-IL-1β       | A19635         | ABclonal     |
2.13. Transmission Electron Microscopy (TEM). The mitochondrial morphology of HNPCs was observed with a TEM instrument (HT7700; Hitachi, Japan) according to a previously described method [37].

2.14. Immunofluorescence Staining. Cells were immobilized, permeabilized, and incubated with the primary antibodies [37]. A concentration of 1:100 was used for the primary antibodies, including antibodies targeting iNOS, MMP13, COX-2, NLRP3, col-2, aggrecan, p65, and p-p65 (Table 2), and a concentration of 1:200 was used for the secondary antibody (ZSGB-Bio, China).

The sections were immersed in absolute ethanol for 5 min, 95% ethanol for 4 min, 90% ethanol for 3 min, 80% ethanol for 2 min, 70% ethanol for 2 min, and distilled water for 2 min. The sections were then washed 3 times with PBS for 5 min each, and 0.1% trypsin was used for antigen repair. The cells were washed 3 times with PBS for 3 min each, blocked with hydrogen peroxide blocking solution, and then washed again 3 times with PBS for 3 min each. Next, the cells were blocked with 5% bovine serum albumin (BSA) for 60 min, incubated with primary antibody at 4°C for 12 h, washed with PBS 3 times for 5 min each, incubated with secondary antibody at room temperature for 2 h, and washed with PBS 3 times for 5 min each. Nuclei were stained with DAPI and examined under a fluorescence microscope. A concentration of 1:100 was used for the primary antibodies, including antibodies targeting col-2, MMP13, IL-1β, COX-2, p-ERK, and p-AKT (Table 2), and a concentration of 1:200 was used for the secondary antibody (ZSGB-Bio, China). Images were captured with a Pannoramic 250 FLASH scanner (3DHISTECH, Hungary).

2.15. Statistical Analysis. The data are expressed as the mean ± standard deviation (SD) and were analyzed using GraphPad Prism v.5.0 software (GraphPad Software Inc., USA). Differences between groups were evaluated by one-way analysis of variance (ANOVA) with Tukey’s post hoc test. A p value <0.05 was considered significant, and significance was denoted as follows: *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001, *p < 0.05, **p < 0.01 and ***p < 0.001.

3. Results

3.1. Effects of HT on HNPC Viability. The results (Figure 1) showed that a cytotoxic effect of HT was not obvious at concentrations of 0, 20, 50, and 100 μM. At the HT concentration of 100 μM, cell viability was slightly decreased compared with that at the other concentrations, but there was no significant difference in viability between the 0 μM and 100 μM treatments. However, cell viability was significantly decreased at HT concentrations of 200 μM and 400 μM. Therefore, HT concentrations of 20 and 100 μM were selected for the subsequent experiments.

3.2. HT Protects the Main Components of the IVD by Alleviating Inflammation and Mitigating ECM Degradation. The release of inflammatory cytokines by NP cells is an important motile and pathological factor of IVDD. The increased secretion of ADAMTSs and MMPs is an important pathological process secondary to the inflammatory response, which can accelerate the imbalance of anabolism and catabolism in IVDs, destroy the homeostasis of the IVD, and aggravate IVDD. The qRT-PCR and WB results shown in Figures 2(a)-2(g) and 2(l)-2(o) reveal that the HNPCs were stimulated with 50 ng/mL TNF-α, TNF-α induced increased protein and mRNA levels of iNOS, COX-2, MMP-13, ADAMTS-4, and NLRP3 in HNPCs, which promoted the degradation of IVD components. In contrast, 20 and 100 μM HT treatment significantly inhibited the secretion of inflammatory cytokines that promote the occurrence and progression of IVDD. The immunofluorescence staining results shown in Figure 2(h)-2(k) and 2(p)-2(w) demonstrate that after TNF-α stimulation, the fluorescence intensity resulting from iNOS, COX-2, NLRP3 inflammasome, and MMP-13 staining was increased, indicating that the expression of these catabolism-promoting indicators was increased, and the fluorescence intensity resulting from col-2 and aggrecan staining was significantly decreased. HT treatment significantly reduced the secretion of inflammatory cytokines and significantly increased the fluorescence intensity resulting from col-2 and aggrecan staining.

3.3. HT Maintains Mitochondrial Homeostasis by Inhibiting the NF-κB Signaling Pathway. As illustrated in Figures 3(a)–3(g), following TNF-α treatment, the mRNA level of NF-κB1 increased, a large amount of p65 was transferred from the cytoplasm to the nucleus, and the phosphorylation level of p65 in the nucleus was increased. After HT intervention, the mRNA level of NF-κB1 and the nuclear translocation rate of p65 were significantly decreased, which decreased the expression level of p-p65. As illustrated in Figures 3(h)–3(k), 50 ng/mL TNF-α significantly increased the endogenous ROS content in HNPCs in vitro. Subsequent Mptp experiments revealed that TNF-α led to the opening of the Mptp, which damaged mitochondrial function and triggered mitochondrial apoptosis. HT intervention significantly reduced the increase in endogenous ROS levels induced by TNF-α and protected mitochondrial function by reducing...
Figure 2: Continued.
|       | TNF-α | HT | 0   | 50  | 50  | 50  | 100 |
|-------|-------|----|-----|-----|-----|-----|-----|
|       |       |    |     |     |     |     |     |
| Mean fluorescence intensity |       |    |     |     |     |     |     |
| ***   |       |    |     |     |     |     |     |
| ****  |       |    |     |     |     |     |     |

**Figure 2: Continued.**
Mptp opening. As shown in Figure 3(l), we observed the morphology of mitochondria directly by TEM. After TNF-α treatment, the morphology of HNPC mitochondria was damaged, the mitochondria had become swollen, and the mitochondrial crest had disappeared, which indirectly indicated mitochondrial dysfunction in HNPCs. Moreover, the change in mitochondrial membrane potential was evaluated by JC-1, and the results are shown in Figures 3(m) and 3(n). We found that TNF-α caused a decrease in the mitochondrial membrane potential of HNPCs, as indicated by a decreased red/green fluorescence value, suggesting that normal mitochondrial function was damaged. In contrast, TNF-α-induced pathological changes were significantly mitigated after HT treatment. Assessments of mitochondrial

Figure 2: HT protects the main components of the IVD by alleviating inflammation and mitigating ECM degradation. Note: HNPCs were incubated for 24/48 h with 50 ng/mL TNF-α and 20 or 100 μM HT or were left untreated. The expression of iNOS (a), COX-2 (b), MMP-13 (c), and ADAMTS-4 (d) was assayed by qRT–PCR. Protein levels of iNOS (e, f) and COX-2 (e, g) were assessed by WB. Immunofluorescence staining was used to assess the COX-2 (h, j), and iNOS (i, k) levels in HNPCs treated with TNF-α and HT. Scale bar: 50 μm. Western blot detection for the expression of ADAMTS-4 (l, m), NLRP3 (l, n), and MMP13 (l, o) in each group. Immunofluorescence staining of NLRP3 (p, r), col-2 (q, s), aggrecan (t, w), and MMP-13 (u, v) in HNPCs. Scale bar: 50 μm.
Figure 3: Continued.
Figure 3: Continued.
Figure 3: Continued.
morbidity showed that HT reduced the number of mitochondria with abnormal morphology, reduced the opening of the Mptp, and alleviated damaged mitochondrial function by improving mitochondrial membrane potential. As shown in Figures 3(o) and 3(p), TNF-α induced apoptosis in 13.4% of HNPCs, whereas HT significantly reduced the apoptosis rate of HNPCs: the apoptosis rate of HNPCs treated with 20 μM HT was 8.49%, and that of HNPCs treated with 100 μM HT was 5.18%. After TNF-α treatment, the expression of c-caspase3 and Bax (employed as a proapoptotic evaluation index) in HNPCs increased, while the expression of Bcl-2 (serving as an antiapoptotic evaluation index) decreased. HT treatment decreased the production of proapoptotic indicators and increased the secretion of antiapoptotic indicators.

3.4. HT Alleviates IVDD in a Rat Needle Puncture Model In Vivo. The HE staining results in Figures 4(b) and 4(g) show that the caudal space in rats was narrowed after puncture. Sagittal pathological staining of the IVD revealed structural disorder, and the structures of the NP and AF could not be distinguished. HT injection mitigated the degeneration of the IVD in rats. The pathological results showed that the two adjacent spaces in the rat caudal vertebra were wider in the HT-treated rats than in the puncture-only rats, and the structure of the NP and AF could be clearly distinguished in the HT-treated rats. As shown in Figure 4(a), SO-FG staining revealed a significantly reduced content of proteoglycans in the degenerative IVD of rats, and the loss of proteoglycans was alleviated by HT treatment. As illustrated in Figures 4(c) and 4(d), picrosirius red staining and polarized light results showed that HT treatment significantly mitigated the loss of collagen content in rat IVDs caused by needle puncture. As illustrated in Figures 4(e)–4(i), HT reduced MMP-13 expression, thereby preventing the loss of col-2 expression caused by excessive catabolic enzyme production.

3.5. HT Inhibits the LPS-Induced Microglial Inflammatory Response. To assess the pathological process, we examined the mechanism by which HT reduces the inflammatory response of microglia to identify a new treatment method for relieving neuropathic pain. As shown in Figures 5(a)–5(d), microglial stimulation with 1 μg/mL LPS resulted in the release of inflammatory cytokines and increased the levels of secreted IL-1β, IL-6, COX-2, and iNOS mRNA. The expression of IL-1β, IL-6, COX-2, and iNOS in microglia was significantly inhibited after HT stimulation. As shown in Figures 5(e)–5(j), LPS treatment increased the inflammatory response of microglia, resulting in increased secretion of COX-2, NLRP3, TNF-α, IL-6, and iNOS. However, HT treatment inhibited this pathological process by reducing the expression of these inflammatory cytokines. As shown in Figures 5(k)–5(n), immunofluorescence staining revealed that HT decreased the fluorescence intensity resulting from COX-2 and iNOS staining, indicating that HT played a role in maintaining the inflammatory homeostasis of microglia.

3.6. HT Alleviates Neuropathic Pain and Reduces the Inflammatory Response in Rats after CCD. We further explored the role of HT in alleviating neuropathic pain in rats by establishing a rat model of CCD and intrathecally administering HT. PWMT and TPWL (behavioral evaluation indices) were measured in the rats every two days beginning on the second day after surgery. The PWMT and TPWL values in the rats in the CCD model group continuously decreased from the 2nd day to the 8th day after surgery and began to recover on the 8th day after surgery. As illustrated in Figures 6(a) and 6(b), HT was injected on the second day after the establishment of the CCD model. The PWMT and TPWL values of the rats had improved beginning on day 2 after HT injection and continued to improve through day 14.

Inhibiting the expression of various proinflammatory cytokines in microglia ameliorates the worsening of

![Figure 3: HT maintains mitochondrial homeostasis by inhibiting the NF-κB signaling pathway. Note: HNPCs were incubated for 1 h with 50 ng/mL TNF-α and 20 or 100 μM HT or were left untreated. (a) qRT-PCR measurement of NF-κB1 levels in each group. (b, c) HNPCs were cultured according to the methods described above; Western blot measurement of p-p65 levels was performed. (d, f) The nuclear translocation rate of p65 was assessed by immunofluorescence staining. Scale bars: 50 μm. (e, g) The expression level of p-p65 was measured using immunofluorescence staining. Scale bar: 50 μm. (h, i) Endogenous ROS levels in HNPCs were measured with a DCFH-DA probe. Scale bar: 50 μm. (j, k) Mptps in HNPCs were assayed by Mptp assay. Scale bar: 50 μm. (l) Mitochondrial morphology was assessed by TEM. Scale bars: 25 μm. HNPCs were incubated for 48 h with 50 ng/mL TNF-α and 20 or 100 μM HT or were left untreated. (m, n) The mitochondrial membrane potential in HNPCs was assessed by JC-1 staining. Scale bar: 50 μm. (o) Flow cytometry was used to evaluate the apoptotic ratio of HNPCs in each group. (p) Western blot measurement of c-caspase3, Bax, and Bcl-2 levels in HNPCs was performed.

![Table: Western blot measurement of c-caspase3, Bax, and Bcl-2 in HNPCs]

| Protein    | 0 μM | 20 μM | 100 μM | 50 μM | 100 μM |
|------------|------|-------|--------|-------|--------|
| C-Caspase3 | 17 KD| 21 KD | 26 KD  | 37 KD | 17 KD  |
| BAX        | 21 KD| 26 KD | 37 KD  | 26 KD | 37 KD  |
| Bcl-2      | 21 KD| 26 KD | 37 KD  | 26 KD | 37 KD  |
| GAPDH      | 21 KD| 26 KD | 37 KD  | 26 KD | 37 KD  |
neuropathic pain. As illustrated in Figures 6(c)–6(f), the protein levels of COX-2, IL-6, and TNF-α in the SDH of rats increased after CCD. As illustrated in Figures 6(g)–6(j), immunofluorescence staining showed that HT decreased the fluorescence intensity resulting from IL-1β and COX-2 staining. Notably, HT reduced the production of inflammatory cytokines in the SDH after CCD, indicating that it played a role in alleviating neuropathic pain.

3.7. HT Alleviates Neuropathic Pain by Inhibiting the PI3K/AKT and ERK Signaling Pathways. As shown in Figures 7(a)–7(c), LPS stimulation activated the PI3K/AKT and ERK signaling pathways by increasing the levels of p-ERK and p-AKT in microglia. In addition, HT inhibited PI3K/AKT and ERK signaling pathway activation by decreasing the p-ERK and p-AKT levels. In verifying our experimental results, we found that the expression of p-ERK and p-AKT increased in rats after CCD, suggesting that the PI3K/AKT and ERK signaling pathways are involved in the development of neuropathic pain. However, intrathecal injection of HT significantly reduced the expression levels of p-ERK and p-AKT in the SDH of rats. These findings indicate that intrathecal injection of HT inhibited the activation of the PI3K/AKT and ERK signaling pathways by reducing the levels of p-ERK and p-AKT in the SDH (Figures 7(d)–7(g)).

HNPCs were incubated for 2 h with 1 μg/mL LPS and 20 or 100 μM HT or were left untreated. (a–c) Western blot analysis of AKT, p-AKT, ERK, and p-ERK expression in HNPCs. (d–g) Representative immunofluorescence staining images of p-AKT and p-ERK expression in the SDH in the PBS control, HT, and needle puncture groups.
Figure 5: Continued.
control group, sham group, CCD group, and CCD group after HT treatment were obtained by immunofluorescence staining. \(N = 5\), scale bar: 50 µm.

Specific mechanisms by which HT alleviates IVDD and neuropathic pain. HT ameliorates the inflammatory response and ECM degeneration, reduces the apoptosis rate, alleviates mitochondrial dysfunction, and maintains IVD homeostasis by inhibiting the NF-κB signaling pathway. HT reduces the inflammatory response and ameliorates neuropathic pain by inhibiting the PI3K/AKT and ERK signaling pathways.

4. Discussion

IVDD is caused by multiple pathological factors, including genetic factors, trauma, excessive mechanical loads, aging, and smoking [40]. In response to various pathological factors, the expression of inflammatory cytokines and chemokines is upregulated in IVD cells [6, 41, 42]. Subsequently, the expression of the catabolic molecules ADAMTSs and MMPs is increased in IVD cells [43, 44]. Catabolic molecules from NP and AF cells promote ECM degradation. Therefore, inhibition of the inflammatory responses and IVD catabolism is important for alleviating IVDD. TNF-α is commonly utilized to simulate the local microenvironment. In the current study, HT improved the inflammatory response of HNPCs, alleviated the degradation of the ECM, and significantly inhibited the loss of major components of the IVD. Therefore, HT balances the relationship between catabolism and anabolism in the IVD and inhibits the loss of major IVD components by inhibiting the expression of enzymes that promote catabolism. In addition, TNF-α plays an important role in mediating ECM degradation by inducing NLRP3 inflammasome activation [45]. In the current study, HT
significantly reduced the increase in the expression of the NLRP3 inflammasome observed during IVDD, thereby ameliorating ECM degradation.

The NF-κB signaling pathway triggers multiple pathological processes that lead to IVDD, including the inflammatory response, matrix degradation, and imbalance in mitochondrial homeostasis [45]. Therefore, we aimed to explore the potential regulatory mechanism of HT in the inhibition of the NF-κB signaling pathway in the pathological process of IVDD and thereby identify appropriate therapeutic targets for improving or even blocking IVDD. In our study, TNF-α was found to increase the expression of NF-κB1, and TNF-α induced the phosphorylation of p65 in the nucleus by increasing its nuclear translocation rate, thereby increasing the expression of p-p65 protein. Our current study demonstrated that HT inhibits the TNF-α-induced COX-2 and IL-6 expression. Representative immunofluorescence staining images of IL-1β (g, i) and COX-2 (h, j) staining are shown.

**Figure 6:** HT alleviates neuropathic pain and reduces the inflammatory response in rats after CCD. (a) PWMT was calculated every 2 days after CCD to assess the mechanical pain in the ipsilateral posterior claw of rats. N = 5. *CCD group vs. Control group, # CCD group vs. CCD + HT group. (b) TPWL was calculated every 2 days after CCD to assess the pain in the ipsilateral posterior claw of rats. N = 5. (c–f) The expression levels of COX-2 (c, d), IL-6 (c, e), and TNF-α (c, f) in the SDH of rats were determined by WB. N = 5. Representative immunofluorescence staining images of IL-1β (g, i) and COX-2 (h, j) staining are shown. N = 5, scale bar: 20 μm.
Figure 7: HT alleviates neuropathic pain by inhibiting the PI3K/AKT and ERK signaling pathways.
activation of the NF-κB signaling pathway by inhibiting p65 nuclear translocation and phosphorylation.

An imbalance in mitochondrial homeostasis can lead to abnormal increases in ROS and secondary oxidative stress reactions as well as decreases in mitochondrial membrane potential. These phenomena disrupt the homeostasis of energy metabolism in the IVD, resulting in an imbalance of anabolism and catabolism, and subsequently causing the apoptosis of NP cells and exacerbating IVDD progression [45]. Our results showed that HT can significantly inhibit the activation of the NF-κB signaling pathway. Moreover, HT reduced the opening of the Mptp and the loss of mitochondrial membrane potential by reducing the production of ROS in HNPCs caused by TNF-α, which was verified by assessments of mitochondrial morphology. HT treatment significantly inhibited the increase in the proapoptotic index and increased the antiapoptotic index. Therefore, HT can reduce apoptosis in HNPCs by maintaining mitochondrial homeostasis during IVDD.

Next, we used a rat needle puncture degeneration model to evaluate the role of HT in alleviating IVDD. HT can alleviate stenosis in the caudal space caused by needle puncture, prevent col-2 loss, and reduce MMP-13 expression. Thus, HT maintains IVD homeostasis by inhibiting the pathogenesis of the IVD.

With the exacerbation of IVDD, the NP may herniate and compress the dural sac and surrounding nerve tissue, thereby inducing neuropathic pain [16]. Therefore, much effort is being made to identify drugs that can relieve IVDD and neuropathic pain to improve the symptoms of LBP and the quality of life of patients. Because the IVD is a tissue severely lacking blood supply [46], local puncture injection is an important means of delivering drugs to NP cells. Since the dural sac is posterior to the IVD, we envision delivering the drug to the dural sac by a single puncture to relieve neuropathic pain and then adjusting the direction of the puncture needle to deliver the drug into the NP tissue to relieve IVDD. Therefore, a single puncture can solve these two clinical problems, reduce pain in patients and the treatment cost, and improve the treatment effect.

Microglia in the SDH release a variety of inflammatory cytokines that initiate neuropathic pain [47]. Therefore, inhibition of the inflammatory response in the SDH is an important method for alleviating neuropathic pain. In the rat CCD model of the present study, the secretion of proinflammatory cytokines in the SDH was increased. Intrathecal injection of HT significantly antagonized the expression of inflammatory cytokines in the SDH after CCD. In vitro experiments showed that HT also significantly reduced the levels of inflammatory cytokines in microglia to relieve neuropathic pain.

The PI3K/AKT and ERK signaling pathways play important roles in the development of neuropathic pain. Inhibition of PI3K/AKT and ERK signaling pathway activation is an important approach for treating neuropathic pain. ERK signaling pathway activation leads to the production of various cytokines, including TNF-α, IL-1β, COX-2, and iNOS, that are involved in the enhancement of neuropathic pain [48–50]. The PI3K/AKT pathway modulates nociceptive information and mediates central sensitization induced by noxious stimuli [51, 52]. Inhibition of PI3K/AKT significantly reduces inflammation and neuropathic pain [53, 54]. Our cell and animal experiments showed that HT plays an important role in inhibiting the ERK and AKT signaling pathways by reducing the expression of p-ERK and p-AKT.
5. Conclusions

In conclusion, HT inhibits inflammatory responses, attenuates oxidative stress, and ameliorates mitochondrial function to maintain IVD homeostasis by inhibiting the NF-κB signaling pathway. HT alleviates neuropathic pain by inhibiting the PI3K/AKT and ERK signaling pathways. Therefore, HT ameliorates IVDD and its secondary neuropathic pain. These findings suggest a new approach for treatment (Figure 8).

Abbreviations

| Abbreviation | Description |
|--------------|-------------|
| LBP | Low back pain |
| IVDD | Intervertebral disc degeneration |
| IVD | Intervertebral disc |
| LPS | Lipopolysaccharide |
| COX-2 | Cyclooxygenase-2 |
| iNOS | Inducible nitric oxide synthase |
| NLRP3 | NOD-like receptor thermal protein domain associated protein 3 |
| NF-κB | Nuclear factor kappa-B |
| PI3K | Phosphatidylinositol 3-kinase |
| AKT | Protein kinase B |
| ERK | Extracellular regulated protein kinase |
| ADAMTS | A disintegrin and metalloproteinase with thrombospondin motifs |
| MMP | Matrix metalloproteinase |
| ROS | Reactive oxygen species |
| TNF-α | Tumor necrosis factor-α |
| IL | Interleukin |
| Coll-2 | Collagen-2 |
| NP | Nucleus pulposus |
| AF | Annulus fibrosus |
| HNPC | Human nucleus pulposus cell |
| HT | Hydroxytyrosol |
| JOA | Japanese Orthopaedic association |
| SD | Standard deviation |
| DCFH-DA | Dichlorodihydrofluorescein diacetate |
| ECM | Extracellular matrix |
| HE | Hematoxylin and eosin |
| SO-FG | Safranin O and fast green staining |
| TEM | Transmission electron microscopy |
| c-caspase3 | Cleaved caspase-3 |
| p-p65 | Phosphorylated p65 |
| p-AKT | Phosphorylated AKT |
| p-ERK | Phosphorylated ERK |
| SDH | Spinal dorsal horn |
| CCD | Chronic compression of the dorsal root ganglion |
| PWMT | Paw withdrawal mechanical threshold |
| TPWL | Thermal paw withdrawal latency |
| qRT–PCR | Quantitative real-time PCR |
| Mptp | Mitochondrial permeability transition pore |

Additional Points

**Institutional Review Board Statement.** The study was approved by the Institutional Ethics Review Board of Chinese PLA General Hospital (2021-323-01). The experimental protocol was established according to the guidelines of the Manipulative Technique for the Care and Use of Laboratory Animals, China, and approved by the Animal Ethical and Welfare Committee of Chinese PLA General Hospital.

**Consent**

The study was approved by the Institutional Ethics Review Board of Chinese PLA General Hospital with written informed consents obtained from each patient.

**Conflicts of Interest**

The authors declare no conflicts of interest.

**Authors’ Contributions**

Haichao Yu is responsible for the conceptualization, methodology, data curation, formal analysis, writing-original draft, and writing-review and editing. Zhen Zhang is responsible for the methodology, data curation, formal analysis, and writing-original draft. Fahong Wei is responsible for the methodology and data curation. Guowei Hou is responsible for the methodology and formal analysis. Yonggang You is responsible for the data curation. Xiangyu Wang and Shiqi Cao are responsible for the methodology. Xiaoqiang Yang, Weibo Liu, and Shaofu Zhang are responsible for the methodology and data curation. Fanqi Hu is responsible for the supervision, conceptualization, and funding acquisition. Xuesong Zhang is responsible for the supervision, conceptualization, and funding acquisition. Xuesong Zhang is responsible for the supervision, conceptualization, and funding acquisition. Fanqi Hu is responsible for the supervision, conceptualization, and funding acquisition. Xuesong Zhang is responsible for the supervision, conceptualization, and funding acquisition. Fanqi Hu is responsible for the supervision, conceptualization, and funding acquisition.

**Acknowledgments**

This study was supported by the grants from the National Natural Science Foundation of China (Grant No. 81972128 to Xuesong Zhang) and Application of Clinical Features of Capital City of Science and Technology Commission China BEIJING Special subject (Z181100001718180 to Xuesong Zhang); National Natural Science Foundation of China (Grant No. 82202744 to Fanqi Hu).

**References**

[1] R. A. Deyo and Y. J. Tsui-Wu, "Descriptive epidemiology of low-back pain and its related medical care in the United States," *Spine (Phila Pa 1976)*, vol. 12, no. 3, pp. 264–268, 1987.
[2] P. Cote, J. D. Cassidy, and L. Carroll, "The Saskatchewan health and back pain Survey," *Spine (Phila Pa 1976)*, vol. 23, no. 15, pp. 1689–1698, 1998.
[3] A. N. Khan, H. E. Jacobsen, J. Khan et al., "Inflammatory biomarkers of low back pain and disc degeneration: a review,"
Annals of the New York Academy of Sciences, vol. 1410, no. 1, pp. 68–84, 2017.

[4] X. Qiu, M. Zhuang, Z. Lu et al., “RIPK1 suppresses apoptosis mediated by TNF and caspase-3 in intervertebral discs,” Journal of Translational Medicine, vol. 17, no. 1, p. 135, 2019.

[5] P. H. Wu, H. S. Kim, and I. T. Jang, “Intervertebral disc diseases PART 2: a review of the current diagnostic and treatment strategies for intervertebral disc disease,” International Journal of Molecular Sciences, vol. 21, no. 6, p. 2135, 2020.

[6] M. V. Rishbud and I. M. Shapiro, “Role of cytokines in intervertebral disc degeneration: pain and disc content,” Nature Reviews Rheumatology, vol. 10, no. 1, pp. 44–56, 2014.

[7] C. Wang, X. Yu, Y. Yan et al., "Tumor necrosis factor-alpha: a key contributor to intervertebral disc degeneration," Acta Biochimica et Biophysica Sinica Shanghai, vol. 49, no. 1, pp. 1–13, 2017.

[8] M. Saberi, X. Zhang, and A. Mobasheri, “Targeting mitochondrial dysfunction with small molecules in intervertebral disc aging and degeneration,” GeroScience, vol. 43, no. 2, pp. 517–537, 2021.

[9] H. Li, J. Slone, and T. Huang, “The role of mitochondrial-related nuclear genes in age-related common disease,” Mitochondrion, vol. 53, pp. 38–47, 2020.

[10] L. Kang, Q. Xiang, S. Zhan et al., “Restoration of autophagic flux rescues oxidative damage and mitochondrial dysfunction to protect against intervertebral disc degeneration,” Oxidative Medicine and Cellular Longevity, vol. 2019, Article ID 7810320, 27 pages, 2019.

[11] L. Colloca, T. Ludman, D. Bouhassira et al., “Neuropathic pain,” Nature Reviews. Disease Primers, vol. 3, no. 1, p. 17002, 2017.

[12] R. Kuner, "Central mechanisms of pathological pain,” Nature Medicine, vol. 16, no. 11, pp. 1258–1266, 2010.

[13] P. M. Grace, M. R. Hutchinson, S. F. Maier, and L. R. Watkins, “Pathological pain and the neuroimmune interface,” Nature Reviews Immunology, vol. 14, no. 4, pp. 217–231, 2014.

[14] A. I. Basbaum, D. M. Bautista, G. Scherrer, and D. Julius, “Cellular and molecular mechanisms of pain,” Cell, vol. 139, no. 2, pp. 267–284, 2009.

[15] S. M. Rothman, Z. Huang, K. E. Lee, C. L. Weisshaar, and B. A. Winkelstein, “Cytokine mRNA expression in painful radiculopathy,” The Journal of Pain, vol. 10, no. 1, pp. 90–99, 2009.

[16] X. Y. Lin, J. Yang, H. M. Li, S. J. Hu, and J. L. Xing, “Dorsal root ganglion compression as an animal model of sciatica and low back pain,” Neuroscience Bulletin, vol. 28, no. 5, pp. 618–630, 2012.

[17] M. A. Thacker, A. K. Clark, F. Marchand, and S. B. Mcmahon, “Pathophysiology of peripheral neuropathic pain: immune cells and molecules,” Anesthesia and Analgesia, vol. 105, no. 3, pp. 838–847, 2007.

[18] G. Moalem and D. J. Tracey, “Immune and inflammatory mechanisms in neuropathic pain,” Brain Research Reviews, vol. 51, no. 2, pp. 240–264, 2006.

[19] J. Y. Lee, H. Y. Choi, B. G. Ju, and T. Y. Yune, “Estrogen alleviates neuropathic pain induced after spinal cord injury by inhibiting microglia and astrocyte activation,” Biochimica et Biophysica Acta - Molecular Basis of Disease, vol. 1864, no. 7, pp. 2472–2480, 2018.

[20] P. Liu, J. Cheng, S. Ma, and J. Zhou, “Paconiflorin attenuates chronic constriction injury-induced neuropathic pain by suppressing spinal NLRP3 inflammasome activation,” Inflammopharmacology, vol. 28, no. 6, pp. 1495–1508, 2020.

[21] S. Pu, S. Li, Y. Xu, J. Wu, Y. Lv, and D. Du, “Role of receptor-interacting protein 1/receptor-interacting protein 3 in inflammation and necrosis following chronic constriction injury of the sciatic nerve,” Neuroreport, vol. 29, no. 16, pp. 1373–1378, 2018.

[22] R. S. Tonkin, C. Bowles, C. J. Perera et al., “Attenuation of mechanical pain hypersensitivity by treatment with peptide5, a connexin-43 mimetic peptide, involves inhibition of NLRP3 inflammasome in nerve-injured mice,” Experimental Neurology, vol. 300, pp. 1–12, 2018.

[23] N. Kiguchi, Y. Kobayashi, and S. Kishioka, “Chemokines and cytokines in neuroinflammation leading to neuropathic pain,” Current Opinion in Pharmacology, vol. 12, no. 1, pp. 55–61, 2012.

[24] M. W. Salter and S. Beggs, “Sublime microglia: expanding roles for the guardians of the CNS,” Cell, vol. 158, no. 1, pp. 15–24, 2014.

[25] Y. Kawasaki, L. Zhang, J. K. Cheng, and R. R. Ji, “Cytokine mechanisms of central sensitization: distinct and overlapping role of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha in regulating synaptic and neuronal activity in the superficial spinal cord,” Journal of Neuroscience, vol. 28, no. 20, pp. 5189–5194, 2008.

[26] K. Ren and R. Duhner, “Interactions between the immune and nervous systems in pain,” Nature Medicine, vol. 16, no. 11, pp. 1267–1276, 2010.

[27] N. Martinez, M. Herrera, L. Frias et al., “A combination of hydroxytyrosol, omega-3 fatty acids and curcumin improves pain and inflammation among early stage breast cancer patients receiving adjuvant hormonal therapy: results of a pilot study,” Clinical & Translational Oncology, vol. 21, no. 4, pp. 489–498, 2019.

[28] E. Scoditti, A. Nestola, M. Massaro et al., “Hydroxytyrosol suppresses MMP-9 and COX-2 activity and expression in activated human monocytes via PKCα and PKCβ1 inhibition,” Atherosclerosis, vol. 232, no. 1, pp. 17–24, 2014.

[29] K. de la Torre-Carbot, O. Jauregui, E. Gimeno, A. I. Castellote, R. M. Lamuela-Raventos, and M. C. Lopez-Sabater, “Characterization and quantification of phenolic compounds in olive oils by solid-phase extraction, HPLC-DAD, and HPLC-MS/MS,” Journal of Agricultural and Food Chemistry, vol. 53, no. 11, pp. 4331–4340, 2005.

[30] M. Robles-Almazan, M. Pulido-Moran, J. Moreno-Fernandez et al., “Hydroxytyrosol: bioavailability, toxicity, and clinical applications,” Food Research International, vol. 105, pp. 654–667, 2018.

[31] R. M. de Pablos, A. M. Espinosa-Oliva, R. Hornero-Ortega, M. Cano, and S. Arguelles, “Hydroxytyrosol protects from aging process via AMPK and autophagy; a review of its effects on cancer, metabolic syndrome, osteoporosis, immune-mediated and neurodegenerative diseases,” Pharmacological Research, vol. 143, pp. 58–72, 2019.

[32] A. Facchini, S. Cetrullo, S. D’Adamo et al., “Hydroxytyrosol prevents increase of osteoarthritis markers in human chondrocytes treated with hydrogen peroxide or growth-related oncogene α,” PloS One, vol. 9, no. 10, article e109724, 2014.

[33] S. Silva, B. Sepodes, J. Rocha et al., “Protective effects of hydroxytyrosol-supplemented refined olive oil in animal models of acute inflammation and rheumatoid arthritis,”
Journal of Nutritional Biochemistry, vol. 26, no. 4, pp. 360–368, 2015.

[34] D. Gong, C. Geng, L. Jiang, J. Cao, H. Yoshimura, and L. Zhong, “Effects of hydroxytyrosol-20 on carrageenan-induced acute inflammation and hyperalgesia in rats,” Phytoremediation Research, vol. 23, no. 5, pp. 646–650, 2009.

[35] R. Takeda, T. Koike, I. Taniguchi, and K. Tanaka, “Double-blind placebo-controlled trial of hydroxytyrosol of _Olea europea_ on pain in gonarthrosis,” Phytomedicine, vol. 20, no. 10, pp. 861–864, 2013.

[36] L. Q. Zhi, S. X. Yao, H. L. Liu, M. Li, N. Duan, and J. B. Ma, “Hydroxytyrosol inhibits the inflammatory response of osteoarthritis chondrocytes via SIRT6-mediated autophagy,” Molecular Medicine Reports, vol. 17, no. 3, pp. 4035–4042, 2018.

[37] H. Yu, G. Hou, J. Cao, Y. Yin, Y. Zhao, and L. Cheng, “Mangiferin Alleviates Mitochondrial ROS in Nucleus Pulposus Cells and Protects against Intervertebral Disc Degeneration via Suppression of NF- B Signaling Pathway,” Oxidative Medicine and Cellular Longevity, vol. 2021, Article ID 6632786, 27 pages, 2021.

[38] L. Zhang, J. Zhang, X. Jiang et al., “Hydroxytyrosol Inhibits LPS-Induced Neuroinflammatory Responses via Suppression of TLR-4-Mediated NF-κB Pathway,” European Cells & Materials, vol. 30, pp. 104–117, 2015.

[39] P. Andrade, G. Hoogland, M. A. Garcia, H. W. Steinbusch, M. A. Daemen, and V. Visser-Vandewalle, “Elevated IL-1β and IL-6 levels in lumbar herniated discs in patients with sciatic pain,” European Spine Journal, vol. 22, no. 4, pp. 714–720, 2013.

[40] N. Rand, F. Reichert, Y. Floman, and S. Rotshenker, “Murine nucleus pulposus-derived cells secrete interleukins-1-beta, -6, and -10 and granulocyte-macrophage colony-stimulating factor in cell culture,” Spine (Phil a Pa 1976), vol. 22, no. 22, pp. 2598–2601, 1997.

[41] A. J. Pockert, S. M. Richardson, C. L. le Maître et al., “Modified expression of the ADAMTS enzymes and tissue inhibitor of metalloproteinases 3 during human intervertebral disc degeneration,” Arthritis and Rheumatism, vol. 60, no. 2, pp. 482–491, 2009.

[42] B. E. Bachmeier, A. Nerlich, N. Mittermaier et al., “Matrix metalloproteinase expression levels suggest distinct enzyme roles during lumbar disc herniation and degeneration,” European Spine Journal, vol. 18, no. 11, pp. 1573–1586, 2009.

[43] G. Z. Zhang, M. Q. Liu, H. W. Chen et al., “NF-κB signalling pathways in nucleus pulposus cell function and intervertebral disc degeneration,” Cell Proliferation, vol. 54, no. 7, article e13057, 2021.

[44] S. Roberts, H. Evans, J. Trivedi, and J. Menage, “Histology and pathology of the human intervertebral disc,” The Journal of Bone and Joint Surgery. American Volume, vol. 88, suppl_2, pp. 10–14, 2006.

[45] A. Ellis and D. L. Bennett, “Neuroinflammation and the generation of neuropathic pain,” British Journal of Anaesthesia, vol. 111, no. 1, pp. 26–37, 2013.

[46] Z. Xu, B. R. Wang, X. Wang et al., “ERK1/2 and p38 mitogen-activated protein kinase mediate iNOS-induced spinal neuron degeneration after acute traumatic spinal cord injury,” Life Sciences, vol. 79, no. 20, pp. 1895–1905, 2006.

[47] K. Popiolek-Barczyk, N. Kolosowska, A. Pietrowska et al., “Parthenolide relieves pain and promotes M2 microglia/macrophage polarization in rat model of neuropathy,” Neural Plasticity, vol. 2015, Article ID 676473, 15 pages, 2015.

[48] E. Rojewska, K. Popiolek-Barczyk, N. Kolosowska et al., “PD98059 influences immune factors and enhances opioid analgesia in model of neuropathy,” PLoS One, vol. 10, no. 10, article e138583, 2015.

[49] R. Sun, J. Yan, and W. D. Willis, “Activation of protein kinase B/Akt in the periphery contributes to pain behavior induced by capsaicin in rats,” Neuroscience, vol. 144, no. 1, pp. 286–294, 2007.

[50] L. N. Yu, X. L. Zhou, J. Yu et al., “PI3K contributed to modulation of spinal nociceptive information related to ephrinsB1/2,” PLoS One, vol. 7, no. 8, article e40930, 2012.

[51] M. Jana, A. Jana, X. Liu, S. Ghosh, and K. Pahan, “Involvement of phosphatidylinositol 3-kinase-mediated up-regulation of I kappa B alpha in anti-inflammatory effect of gemfibrozil in microglia,” Journal of Immunology, vol. 179, no. 6, pp. 4142–4152, 2007.

[52] S. P. Jiang, Z. D. Zhang, L. M. Kang, Q. H. Wang, L. Zhang, and H. P. Chen, “Celecoxib reverses oxaliplatin-induced neuropathic pain through inhibiting PI3K/Akt2 pathway in the mouse dorsal root ganglion,” Experimental Neurology, vol. 275, Part 1, pp. 11–16, 2016.